- Home
- CLLS vs SABA Comparison
CLLS vs SABA Comparison
Compare CLLS & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SABA
- Stock Information
- Founded
- CLLS 1999
- SABA 1988
- Country
- CLLS France
- SABA United States
- Employees
- CLLS N/A
- SABA N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- CLLS Health Care
- SABA
- Exchange
- CLLS Nasdaq
- SABA Nasdaq
- Market Cap
- CLLS 240.2M
- SABA 245.8M
- IPO Year
- CLLS 2007
- SABA N/A
- Fundamental
- Price
- CLLS $2.01
- SABA $8.63
- Analyst Decision
- CLLS Buy
- SABA
- Analyst Count
- CLLS 2
- SABA 0
- Target Price
- CLLS $8.00
- SABA N/A
- AVG Volume (30 Days)
- CLLS 22.3K
- SABA 290.0K
- Earning Date
- CLLS 11-04-2024
- SABA 01-01-0001
- Dividend Yield
- CLLS N/A
- SABA 12.91%
- EPS Growth
- CLLS N/A
- SABA N/A
- EPS
- CLLS N/A
- SABA N/A
- Revenue
- CLLS $19,635,000.00
- SABA N/A
- Revenue This Year
- CLLS $271.02
- SABA N/A
- Revenue Next Year
- CLLS $33.48
- SABA N/A
- P/E Ratio
- CLLS N/A
- SABA N/A
- Revenue Growth
- CLLS N/A
- SABA N/A
- 52 Week Low
- CLLS $0.96
- SABA $3.64
- 52 Week High
- CLLS $3.77
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- CLLS 41.74
- SABA 61.44
- Support Level
- CLLS $1.95
- SABA $8.34
- Resistance Level
- CLLS $2.06
- SABA $8.73
- Average True Range (ATR)
- CLLS 0.10
- SABA 0.10
- MACD
- CLLS -0.01
- SABA 0.01
- Stochastic Oscillator
- CLLS 33.33
- SABA 74.36
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Templeton Global Income Fund is a closed-end fund. It seeks high current income, with a secondary goal of capital appreciation. Under normal market conditions. The Fund invests at least over 80% of its net assets in income-producing securities, including debt securities of the United States and foreign issuers, including emerging markets.